Publication Topic

Cronin-Fenton D, Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Hansen H, Fryzek J, Lawrence D, Walker J, Mellemgaard A, Rasmussen TR, Shire N, Rigas J, Potter D, Hamilton-Dutoit S, Sorensen HT. PD-L1 expression, EGFR and KRAS mutations in First-Line Therapy (1L) for non-small cell lung cancer (NSCLC) patients. Presented at the 18th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) 2017, October 15-18, 2017, Yokohama, Japan.

Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. 2017. Arteriovenous fistulas for hemodialysis: A systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg 54:513e522.

Friedman D, Fryzek J, Jiang X, Bloomfield A, Ambrose CS, Wong PC. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One. 2017 Mar 2;12(3):e0172512.

Pastula S, Hackett J, Coalson J, Jiang X, Villafana T, Fryzek J. 2017. Hospitalizations for Respiratory Syncytial Virus among adults in the United States, 1997 to 2012.  2017. Open Forum Infectious Diseases 4(1):ofw270.

Ruzin A, Levin-Sparenberg E, Pastula, Jiang X, Fryzek J, Tovchigrechko A, Lu B, Yu L, Hackett J, Villafana T, Esser MT. Characterization of RSV Strains Among U.S. Patients in the OUTSMART RSV Program During 2015-16. Presented at ID Week 2017, October 4-6, 2017, San Diego, CA.

Soff GA, Ray-Coquard I, Marfil Rivera LJ, Fryzek J, Mullins M, Bylsma LC, Park JK. Literature Review of Thrombopoietin Receptor Agonists (TPO-RA) for Chemotherapy-Induced Thrombocytopenia (CIT). Presented at the European Society for Medical Oncology 2017 Congress, September 8-12, 2017, Madrid, Spain.

Ruterbusch JJ, Bylsma LC, Fryzek J, Barlev A, et al. Bicalutamide Treatment Patterns in Elderly Prostate Cancer Patients: A Historical Cohort Study Using the Surveillance, Epidemiology and End Results Program (SEER)-Medicare Database. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, May 20-24, 2017, Boston, MA.

Fryzek JP, Ruterbusch JJ, Garabrant DH, Dalvi T, Beebe-Dimmer JL. Healthcare Resource Utilization and Costs of Care for Mesothelioma Medicare Beneficiaries. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, May 20-24, 2017, Boston, MA.

Cronin-Fenton D, Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Mortensen K, Midta A, Shire N, Brody R, Fryzek J, Lawrence D, Rigas J, Potter D, Walker J, Mellemgaard A, Rasmussen TR, Hamilton-Dutoit S, Sorensen HT. An interim assessment of key biomarkers (programmed cell death receptor ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) in third-line therapy non-small cell lung cancer (NSCLC) patients: A Danish cohort study. Presented at the 41st European Society for Medical Oncology (ESMO) Congress, October 7-11 2016, Copenhagen, Denmark.

Cetin K, Callaghan F, Fryzek J, Bylsma L, Bezold C, Mehta B. Safety and Efficacy/Effectiveness of 2nd-line Treatments in Immune Thrombocytopenia (ITP): A Systematic Review of the Literature. Presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 25-28, 2016, Dublin, Ireland.